Your browser doesn't support javascript.
loading
Future cancer research priorities in the USA: a Lancet Oncology Commission.
Jaffee, Elizabeth M; Dang, Chi Van; Agus, David B; Alexander, Brian M; Anderson, Kenneth C; Ashworth, Alan; Barker, Anna D; Bastani, Roshan; Bhatia, Sangeeta; Bluestone, Jeffrey A; Brawley, Otis; Butte, Atul J; Coit, Daniel G; Davidson, Nancy E; Davis, Mark; DePinho, Ronald A; Diasio, Robert B; Draetta, Giulio; Frazier, A Lindsay; Futreal, Andrew; Gambhir, Sam S; Ganz, Patricia A; Garraway, Levi; Gerson, Stanton; Gupta, Sumit; Heath, James; Hoffman, Ruth I; Hudis, Cliff; Hughes-Halbert, Chanita; Ibrahim, Ramy; Jadvar, Hossein; Kavanagh, Brian; Kittles, Rick; Le, Quynh-Thu; Lippman, Scott M; Mankoff, David; Mardis, Elaine R; Mayer, Deborah K; McMasters, Kelly; Meropol, Neal J; Mitchell, Beverly; Naredi, Peter; Ornish, Dean; Pawlik, Timothy M; Peppercorn, Jeffrey; Pomper, Martin G; Raghavan, Derek; Ritchie, Christine; Schwarz, Sally W; Sullivan, Richard.
  • Jaffee EM; The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ejaffee@jhmi.edu.
  • Dang CV; Ludwig Institute for Cancer Research New York, NY; Wistar Institute, Philadelphia, PA, USA. Electronic address: cdang@licr.org.
  • Agus DB; University of Southern California, Beverly Hills, CA, USA.
  • Alexander BM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Ashworth A; University of California San Francisco, San Francisco, CA, USA.
  • Barker AD; Arizona State University, Tempe, AZ, USA.
  • Bastani R; Fielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
  • Bhatia S; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Bluestone JA; University of California San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Brawley O; American Cancer Society, Atlanta, GA, USA.
  • Butte AJ; University of California San Francisco, San Francisco, CA, USA.
  • Coit DG; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Davidson NE; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
  • Davis M; California Institute for Technology, Pasadena, CA, USA.
  • DePinho RA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diasio RB; Mayo Clinic Cancer Center, Rochester, MN, USA.
  • Draetta G; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Frazier AL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Futreal A; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gambhir SS; Stanford University, Stanford, CA, USA.
  • Ganz PA; Fielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
  • Garraway L; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA; Eli Lilly and Company, Boston, MA, USA.
  • Gerson S; Case Comprehensive Cancer Center, Cleveland, OH, USA.
  • Gupta S; Division of Haematology/Oncology, Hospital for Sick Children, Faculty of Medicine and IHPME, University of Toronto, Toronto, Canada.
  • Heath J; California Institute for Technology, Pasadena, CA, USA.
  • Hoffman RI; American Childhood Cancer Organization, Beltsville, MD, USA.
  • Hudis C; Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Hughes-Halbert C; Medical University of South Carolina and the Hollings Cancer Center, Charleston, SC, USA.
  • Ibrahim R; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Jadvar H; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Kavanagh B; Department of Radiation Oncology, University of Colorado, Denver, CO, USA.
  • Kittles R; College of Medicine, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
  • Le QT; Stanford University, Stanford, CA, USA.
  • Lippman SM; University of California San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • Mankoff D; Department of Radiology and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Mardis ER; The Institute for Genomic Medicine at Nationwide Children's Hospital Columbus, OH, USA; College of Medicine, Ohio State University, Columbus, OH, USA.
  • Mayer DK; University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.
  • McMasters K; The Hiram C Polk Jr MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
  • Meropol NJ; Flatiron Health, New York, NY, USA.
  • Mitchell B; Stanford University, Stanford, CA, USA.
  • Naredi P; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Ornish D; University of California San Francisco, San Francisco, CA, USA.
  • Pawlik TM; Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
  • Peppercorn J; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Pomper MG; The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Raghavan D; Levine Cancer Institute, Carolinas HealthCare, Charlotte, NC, USA.
  • Ritchie C; University of California San Francisco, San Francisco, CA, USA.
  • Schwarz SW; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.
  • Sullivan R; King's College London, London, UK.
Lancet Oncol ; 18(11): e653-e706, 2017 11.
Article en En | MEDLINE | ID: mdl-29208398
ABSTRACT
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Investigación Biomédica / National Cancer Institute (U.S.) / Planificación en Salud / Prioridades en Salud / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País como asunto: America do norte Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Investigación Biomédica / National Cancer Institute (U.S.) / Planificación en Salud / Prioridades en Salud / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País como asunto: America do norte Idioma: En Año: 2017 Tipo del documento: Article